A Systematic Review of the Role of Imaging before Salvage Radiotherapy for Post-prostatectomy Biochemical Recurrence

Clinical Oncology

Volumn 22, Issue 1, 2010, Pages 46-55

  Beresford, M J ^a   Gillatt, D ^b   Benson, R J ^c   Ajithkumar, T ^a  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Biochemical recurrence; bone scan; PET CT; prostascint; prostate cancer; salvage radiotherapy

Indexed keywords

CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RECURRENT CANCER; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 73149109064     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.10.015     Document Type: Article

References (55)

1. Hagan M., Zlotecki R., Medina C., Tercilla O., Rivera I., and Wajsman Z. Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 59 2 (2004) 329-340
2. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 9485 (2005) 572-578
3. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 19 (2006) 2329-2335
4. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181 3 (2009) 956-962
5. Freedland S.J., Sutter M.E., Dorey F., and Aronson W.J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61 2 (2003) 365-369
6. Boccon-Gibod L., Djavan W.B., Hammerer P., et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 58 4 (2004) 382-390
7. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 15 (2007) 2035-2041
8. Jhaveri F.M., Zippe C.D., Klein E.A., and Kupelian P.A. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 54 5 (1999) 884-890
9. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 17 (1999) 1642-1645
10. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 11 (2004) 1325-1332
11. Hayes S.B., and Pollack A. Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol 23 32 (2005) 8204-8211
12. Oesterling J.E., Epstein J.I., and Walsh P.C. Long-term autopsy findings following radical prostatectomy. Urology 29 6 (1987) 584-588
13. Scattoni V., Roscigno M., Raber M., et al. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 44 4 (2003) 407-414
14. Saleem M.D., Sanders H., Abu El Naser M., and El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 51 2 (1998) 283-286
15. Schild S.E., Buskirk S.J., Wong W.W., et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 156 5 (1996) 1725-1729
16. Forman J.D., and Velasco J. Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology (Williston Park) 12 1 (1998) 33-39
17. Swanson G.P., Hussey M.A., and Tangen C.M. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 16 (2007) 2225-2229
18. King C.R., and Spiotto M.T. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 71 1 (2008) 23-27
19. Leventis A.K., Shariat S.F., and Slawin K.M. Local recurrence after radical prostatectomy. Correlation of US features with prostatic fossa biopsy findings. Radiology 219 (2001) 432-439
20. Scattoni V., Roscigno M., Raber M., et al. Biopsy of the vesico-urethral anastomosis after radical prostatectomy: when and how. Eur Urol 38 (2002) 89-95
21. Scattoni V., Montorsi F., Picchio M., et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int 93 5 (2004) 680-688
22. Cher M.L., Bianco F.J., Lam J.S., et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160 4 (1998) 1387-1391
23. Okotie O.T., Aronson W.J., Wieder J.A., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171 6 Pt 1 (2004) 2260-2264
24. Kane C.J., Amling C.L., Johnstone P.A., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61 3 (2003) 607-611
25. Gomez P., Manoharan M., Kim S.S., and Soloway M.S. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated. BJU Int 94 3 (2004) 299-302
26. Dotan Z.A., Bianco Jr. F.J., Rabbani F., et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23 9 (2005) 1962-1968
27. Oyen R.H., van Poppel H.P., Ameye F.E., et al. Lymph node staging of localised prostatic carcinoma with CT and CT-guided fine needle aspiration biopsy: prospective study of 285 patients. Radiology 190 (1994) 315-322
28. Johnstone P.A., Tarman G.J., Riffenburgh R., Rohde D.C., Puckett M.L., and Kane C.J. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol Oncol 3 4 (1997) 108-112
29. Kramer S., Gorich J., Gottfried H.W., et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70 (1997) 995-999
30. Sella T., Schwartz L.H., Swindle P.W., et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231 2 (2004) 379-385
31. Michalski J.M., Lawton C., El Naqa I., et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2009) in press, doi:10.1016/j.ijrobp.2009.02.006.
32. Miralbell R., Vees H., Lozano J., et al. Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 67 2 (2007) 356-361
33. Alonzi R., Padhani A.R., and Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 63 3 (2007) 335-350
34. Haider M.A., Chung P., Sweet J., et al. Dynamic contrast-enhanced magnetic resonance imaging for localisation of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70 2 (2008) 425-430
35. Jackson A.S., Reinsberg S.A., Sohaib S.A., et al. Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol 82 974 (2009) 148-156
36. Cheikh A.B., Girouin N., Colombel M., et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localising prostate cancer before repeat biopsy. Eur Radiol 19 3 (2009) 770-778
37. Sciarra A., Panebianco V., Salciccia S., et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54 3 (2008) 589-600
38. Gibbs P., Tozer D.J., Liney G.P., and Turnbull L.W. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 46 (2001) 1054-1058
39. Haider M.A., van der Kwast T.H., Tanguay J., et al. Combined T2-weighted and diffusion-weighted MRI for localisation of prostate cancer. Am J Radiol 189 (2007) 323-328
40. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 25 (2003) 2491-2499
41. Brush J.P. Positron emission tomography in urological malignancy. Curr Opin Urol 11 2 (2001) 175-179
42. Rinnab L., Mottaghy F.M., Blumstein N.M., et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100 4 (2007) 786-793
43. Scattoni V., Picchio M., Suardi N., et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52 2 (2007) 423-429
44. Schilling D., Schlemmer H.P., Wagner P.H., et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 102 4 (2008) 446-451
45. Pelosi E., Arena V., Skanjeti A., et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 113 6 (2008) 895-904
46. Cimitan M., Bortolus R., Morassut S., et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33 12 (2006) 1387-1398
47. Oyama N., Akino H., Kanamaru H., et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 43 2 (2002) 181-186
48. Vees H., Buchegger F., Albrecht S., et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99 6 (2007) 1415-1420
49. Hinkle G.H., Burgers J.K., Neal C.E., et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 83 4 (1998) 739-747
50. Wilkinson S., and Chodak G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol 172 1 (2004) 133-136
51. Koontz B.F., Mouraviev V., Johnson J.L., et al. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 71 2 (2008) 358-361
52. Raj G.V., Partin A.W., and Polascik T.J. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early recurrent prostate cancer after radical prostatectomy. Cancer 94 (2002) 987-996
53. Petronis J.D., Regan F., and Lin K. Indium-111 capromab pendetide (Prostascint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 23 (1998) 672-677
54. Elgamal A.A., Troychak M.J., and Murphy G.P. Prostascint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37 (1998) 261-269
55. Nagda S.N., Mohideen N., Lo S.S., et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 67 3 (2007) 834-840